4-hydroxytoremifene

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
While estrogen receptor (ER)-targeted therapeutics have clearly been a success in the treatment of breast cancer, the orphan… (More)
Is this relevant?
2004
2004
Estrogen-related receptor gamma (ERRgamma) is an orphan nuclear receptor lacking identified natural ligands. We have addressed… (More)
Is this relevant?
2003
2003
The antiestrogen, tamoxifen, has been extensively used in the treatment and prevention of breast cancer. Although tamoxifen… (More)
Is this relevant?
2001
2001
Tamoxifen remains the endocrine therapy of choice in the treatment of all stages of hormone-dependent breast cancer. However… (More)
Is this relevant?
2000
2000
Tamoxifen is widely prescribed for the treatment of hormone-dependent breast cancer, and it has recently been approved by the… (More)
Is this relevant?
1997
1997
4-Hydroxytamoxifen is a major metabolite of the antiestrogenic drug tamoxifen used in the treatment of women with breast cancer… (More)
Is this relevant?
1997
1997
1997
The aim of the present study was to investigate antioxidativity of the triphenylethylene antiestrogen toremifene. Toremifene and… (More)
  • table 1
  • figure 1
  • figure 4
Is this relevant?
1990
1990
A multicenter phase I pharmacokineticstudy of a new triphenylethylene antiestrogen, toremifene, was examined in 70 patients with… (More)
  • figure 2
  • figure 1
  • table 1
  • figure 4
  • figure 3
Is this relevant?
1990
1990
Toremifene, a new antiestrogenic antitumor compound, has several biologically active metabolites. The hormonal effects of the… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
  • table 5
Is this relevant?